Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
Kamada (NASDAQ: KMDA) will release its third quarter and nine months ended September 30, 2025 financial results on Monday, November 10, 2025 before U.S. market open. Management will host an investor conference call on November 10, 2025 at 8:30 AM Eastern Time to discuss results and answer questions.
Shareholders can join by phone using conference ID 13756537 (U.S.: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) or listen via live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.
Kamada (NASDAQ: KMDA) diffonderà i suoi risultati finanziari del terzo trimestre e dei primi nove mesi terminati il 30 settembre 2025 lunedì 10 novembre 2025 prima dell'apertura del mercato statunitense. Il management terrà una conference call per gli investitori lunedì 10 novembre 2025 alle 8:30 ora orientale per discutere i risultati e rispondere alle domande.
Gli azionisti possono partecipare telefonicamente usando l'ID conferenza 13756537 (USA: 1-877-407-0792; Israele: 1-809-406-247; Internazionale: 1-201-689-8263) o ascoltare via webcast in diretta all'indirizzo https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.
Kamada (NASDAQ: KMDA) hará pública sus resultados financieros del tercer trimestre y de los primeros nueve meses terminados el 30 de septiembre de 2025 el lunes 10 de noviembre de 2025 antes de la apertura del mercado de EE. UU.. La dirección ejecutiva organizará una conferencia telefónica para inversores el 10 de noviembre de 2025 a las 8:30 a. m. hora del Este para discutir los resultados y responder preguntas.
Los accionistas pueden unirse por teléfono usando la ID de conferencia 13756537 (EE. UU.: 1-877-407-0792; Israel: 1-809-406-247; Internacional: 1-201-689-8263) o escuchar vía webcast en directo en https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.
카마다(NASDAQ: KMDA) 는 2025년 9월 30일로 끝나는 3분기 및 9개월 실적을 2025년 11월 10일 월요일 미국 시장 개장 전에 발표합니다. 경영진은 2025년 11월 10일 동부 표준시 8:30에 투자자 컨퍼런스 콜을 개최하여 결과를 논의하고 질문에 답합니다.
주주들은 컨퍼런스 ID 13756537로 전화로 참여할 수 있습니다(미국: 1-877-407-0792; 이스라엘: 1-809-406-247; 국제: 1-201-689-8263) 또는 라이브 웹캐스트 https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662를 통해 시청할 수 있습니다.
Kamada (NASDAQ : KMDA) publiera ses résultats financiers du troisième trimestre et des neuf mois terminés le 30 septembre 2025 le lundi 10 novembre 2025 avant l'ouverture des marchés américains. La direction organisera une conférence téléphonique pour les investisseurs le 10 novembre 2025 à 8h30, heure avancée de l'Est pour discuter des résultats et répondre aux questions.
Les actionnaires peuvent se joindre par téléphone en utilisant l'identifiant de conférence 13756537 (États-Unis : 1-877-407-0792 ; Israël : 1-809-406-247 ; International : 1-201-689-8263) ou écouter via webcast en direct sur https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.
Kamada (NASDAQ: KMDA) wird seine Ergebnisse für das dritte Quartal und die ersten neun Monate zum 30. September 2025 am Montag, den 10. November 2025 vor derUS-Börsenöffnung veröffentlichen. Das Management wird am 10. November 2025 um 8:30 Uhr Eastern Time eine Investoren-Konferenzschaltung abhalten, um die Ergebnisse zu diskutieren und Fragen zu beantworten.
Aktionäre können telefonisch mit der Konferenz-ID 13756537 teilnehmen (USA: 1-877-407-0792; Israel: 1-809-406-247; International: 1-201-689-8263) oder via Live-Webcast unter https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662 zuhören.
كاما-دا (ناسداك: KMDA) ستصدر نتائجها المالية للربع الثالث وللثلاثة أشهر المنتهية في 30 سبتمبر 2025 يوم الإثنين 10 نوفمبر 2025 قبل افتتاح السوق الأمريكية. ستعقد الإدارة مكالمة مؤتمر للمستثمرين في 10 نوفمبر 2025 الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة لمناقشة النتائج والإجابة على الأسئلة. يمكن للمساهمين الانضمام عبر الهاتف باستخدام معرّف المؤتمر 13756537 (الولايات المتحدة: 1-877-407-0792؛ إسرائيل: 1-809-406-247؛ الدولية: 1-201-689-8263) أو الاستماع عبر البث المباشر على https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.
- None.
- None.
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025.
Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689- 8263 (International) using conference I.D. 13756537. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1738840&tp_key=92257bc662.
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
When will Kamada (KMDA) release Q3 and nine months 2025 results?
What time is the Kamada (KMDA) investor conference call on November 10, 2025?
How can investors join the Kamada (KMDA) conference call on November 10, 2025?
Where can I listen to the live webcast of Kamada's (KMDA) November 10, 2025 call?
What periods will Kamada (KMDA) cover in the November 10, 2025 announcement?
Will Kamada (KMDA) management take investor questions on the November 10, 2025 call?
